FDA warns of adverse effects of flea and tick medicine

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated.

SAN DIEGO — The U.S. Food & Drug Administration warned veterinarians and pet owners Thursday that some flea and tick medicine could have potential neurologic adverse events on pets.

The medicines are in the isoxazoline class. These drugs include Bravecto, Credelio, Nexgard and Simparica. While these drugs are FDA approved for the treatment and prevention of flea and tick infestations, pet owners should consult with their veterinarian to determine whether a product in the isoxazoline class is appropriate for use, according to the FDA.

Isoxazoline products have been associated with neurologic adverse reactions such as muscle tremors, ataxia and seizures in some dogs and cats.

If your dog or cat experiences any adverse event while using an isoxazoline product, the FDA recommends first consulting your veterinarian.

For more information, click here.

Notice: you are using an outdated browser. Microsoft does not recommend using IE as your default browser. Some features on this website, like video and images, might not work properly. For the best experience, please upgrade your browser.